Predictors of slow clinical response and extended treatment in patients with extra-pulmonary tuberculosis in Pakistan, A hospital-based prospective study

Author:

Ambreen Atiqa,Tahseen SabiraORCID,Wali Ahmad,Jamil Muhammad,Naqvi Syed Zeeshan Haider,Safdar Nauman,Mustafa TehminaORCID

Abstract

The optimal duration of treatment in different forms of extrapulmonary tuberculosis (EPTB) is not clearly defined. This study aimed to identify predictors of slow clinical response and extended anti-TB treatment in EPTB patients. Socio-demographic, clinical, and microbiological characteristics of EPTB patients registered for anti-TB treatment at a tertiary care hospital, were analysed for identification of predictors of extended treatment. A total of 251 patients (137 lymphadenitis, and 114 pleuritis) were included in the analysis. Treatment was extended to more than 6 months in 58/251 (23%) patients. In the multivariate regression analysis, culture-positive EPTB (p = 0.007) [OR (95% CI) = 3.81 (1.43, 10.11)], history of diabetes (p = 0.014) [OR (95% CI) = 25.18 (1.94, 325.83)], smokeless tobacco use (p = 0.002) [OR (95% CI) = 17.69 (2.80, 111.72)], and slow regression of local signs and symptoms after 2 months of treatment (p < 0.001) [OR (95% CI) = 17.09 [(5.79, 50.39)] were seen to be significantly associated with treatment extension. Identification of predictors of extended treatment can help clinical decisions regarding optimal duration of treatment. Further studies are needed to identify subgroups of EPTB patients who can benefit from a shorter or longer treatment regimen.

Funder

Research Council of Norway

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference46 articles.

1. World Health organization (WHO), Tuberculosis Fact Sheets. 2020 [cited 2021 19 April]; Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis.

2. World Health Organization: Global tuberculosis report. Switzerland: Geneva; 2020; Available from: https://apps.who.int/iris/bitstream/handle/10665/336069/9789240013131-eng.pdf.

3. World Health Organization (WHO), Tuberculosis country, regional and global profiles., Switzerland Geneva; 2020 [cited 2021 July]; Available from: https://www.who.int/teams/global-tuberculosis-programme/data.

4. Controlled trial of 6-month and 8-month regimens in the treatment of pulmonary tuberculosis: the results up to 24 months.;HKC Service;Tubercle,1979

5. World Health Organization: Guidelines for Treatment of Drug-Susceptible Tuberculosis and Patient Care, 2017 Update. Switzerland: Geneva; 2017; Available from: https://apps.who.int/iris/bitstream/handle/10665/255052/9789241550000-eng.pdf.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3